2022. Intermediate results of the prospective randomized controlled trial VOG-01: "Evaluation of the efficacy of neoadjuvant combination hormone therapy in premenopausal patients with ER+ HER2- breast cancer". Voprosy onkologii. 68, 3 (Jul. 2022), 354–361. DOI:https://doi.org/10.37469/0507-3758-2022-68-3-354-361.